Genzyme Corp.'s Phase III win with Mozobil (plerixafor) for non-Hodgkin's lymphoma vindicates those who cheered the high-priced buyout in a bidding war for AnorMED Inc., but the market for the CXCR4 chemokine antagonist might not be huge, and investors still are waiting for results of the trial in multiple myeloma, due in the next few weeks.(BioWorld Today)